3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
978
Other hematologic neoplasm
487
Plasma cell
196
Dermatologic
196
Myeloid
168
Sarcoma
127
Genitourinary
64
CNS
57
Breast
54
Gynecologic
52
Classical hematology
51
Other neoplasm
29
Thoracic
26
Gastrointestinal
19
Head & Neck
10
Endocrine
5
Other solid neoplasm
4
Other
4
NET
1
Conditions
Neuroendocrine Tumors
208
Carcinoid Tumor
26
Neoplasms
22
Pancreatic Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
14
Carcinoma, Neuroendocrine
11
Carcinoma
11
Adenoma, Islet Cell
11
Neoplasm Metastasis
10
Colorectal Neoplasms
9
Lung Neoplasms
8
Serotonin Syndrome
7
Prostatic Neoplasms
7
Adenocarcinoma
7
Pheochromocytoma
6
Gastrointestinal Neoplasms
6
Colonic Neoplasms
6
Breast Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Somatostatinoma
5
Neuroblastoma
5
Melanoma
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Vipoma
4
Sarcoma
4
Rectal Neoplasms
4
Paraganglioma
4
Interventions
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Follicular
×
NET
×
Clear all
NCT02113800
2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2
Completed
40 enrolled